A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.

Jialiang ZhaoYan WuTong XiaoCheng ChengTong ZhangZiyang GaoSiyuan HuZe RenXinze YuFang YangGuiying Li

Published in: Breast cancer research and treatment (2023)

We identified amino acid residues in cyclin D1 that may play key roles in the ADκ-cyclin D1 interaction. A nuclear localization antibody against cyclin D1 (NLS-ADκ) was constructed and successfully expressed in breast cancer cells. NLS-ADκ exerted tumor suppressor effects via blocking the binding of CDK4 to cyclin D1 and inhibiting phosphorylation of RB. The results presented here demonstrate anti-tumor potential of intrabody-based cyclin D1-targeted breast cancer therapy.

Keyphrases

cell cycle
cell proliferation
cancer therapy
cell cycle arrest
breast cancer cells
pi k akt
cell death
climate change
wastewater treatment
binding protein